Table 2 Clinical characteristics of patients in the training and validation cohorts
Characteristics | All cohort (n = 186) | P-value | Training cohort (n = 130) | P-value | Validation cohort (n = 56) | P-value | |||
|---|---|---|---|---|---|---|---|---|---|
Uneventful (n = 124) | Relapse or dead (n = 62) | Uneventful (n = 87) | Relapse or dead (n = 43) | Uneventful (n = 37) | Relapse or dead (n = 19) | ||||
Age (mean ± SD yrs) | 44.5 ± 13.8 | 54.0 ± 9.2 | < 0.001 | 44.3 ± 13.9 | 54.3 ± 9.0 | < 0.001 | 45.0 ± 13.4 | 53.5 ± 9.8 | 0.019 |
CA125 (mean ± SD Iu/L) | 511 ± 884 | 647 ± 1195 | 0.472 | 549 ± 914 | 557 ± 914 | 0.384 | 415 ± 521 | 740 ± 1275 | 0.182 |
Ki67 expression% (mean ± SD) | 25.36 ± 23.23 | 33.31 ± 23.77 | 0.007 | 25.98 ± 24.40 | 32.77 ± 22.78 | 0.024 | 23.89 ± 20.16 | 34.53 ± 25.83 | 0.102 |
FIGO stage(%) | |||||||||
1 | 65 (52) | 20 (33) | 48 (55) | 15 (35) | 17 (46) | 5 (27) | |||
2 | 9 (7) | 7 (11) | 5 (6) | 5 (12) | 4 (11) | 2 (10) | |||
3 | 48 (39) | 28 (45) | 0.005 | 33 (38) | 19 (44) | 0.029 | 15 (41) | 9 (47) | 0.223 |
4 | 2 (2) | 7 (11) | 1 (1) | 4 (9) | 1 (2) | 3 (16) | |||